AstraZeneca

Showing 15 posts of 785 posts found.

Brennan bows to pressure and quits AstraZeneca

April 26, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, David Brennan, Q1, pharma

AstraZeneca’s chief executive David Brennan is to step down from his post following mounting dissatisfaction with his leadership. Brennan, who …

AstraZeneca diabetes drug recommended in Europe

April 23, 2012
Sales and Marketing AstraZeneca, CHMP, FDA, Merck, WHO, diabetes

AstraZeneca and Bristol-Myers Squibb’s new type II diabetes treatment Forxiga has received a positive opinion by European regulators.  The European …

AstraZeneca picture

AstraZeneca to buy Ardea for $1.3 billion

April 23, 2012
Research and Development, Sales and Marketing Ardea, AstraZeneca, febuxostat, gout

AstraZeneca is to buy Ardea Biosciences for $1 billion to help bolster its pipeline. Under the terms of the agreement, …

Steve Yang

Innovating in China’s pharma market

April 12, 2012
Research and Development AstraZeneca, China, R&D, Steve Yang, emerging markets

The challenges that China and the wider Asia region face in healthcare represent big opportunities for multinational pharma companies. Cases of …

Investors ramp up pressure on AZ chief

April 10, 2012
Sales and Marketing AstraZeneca, David Brennan

AstraZeneca’s chief executive David Brennan is coming under increasing pressure from investors, and his future at the firm could be …

Brain image

The brain drain

April 5, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, R&D, brain drain, research and development

Concerns about the growing number of companies disinvesting from neuroscience research have been growing in recent years, and the latest …

AstraZeneca signs respiratory pact with Amgen

April 5, 2012
Research and Development Amgen, AstraZeneca, MedImmune, respiratory

AstraZeneca has bought its way into Amgen’s inflammation portfolio with a $50 million upfront payment to co-develop and commercialise five …

AstraZeneca wins fresh US victory with Seroquel XR

April 2, 2012
Sales and Marketing AZ, AstraZeneca, FDA, Seroquel XR

AstraZeneca is celebrating a US court verdict in its ongoing battle for intellectual property over the extended release version of …

High Court rules against Seroquel XR patent

March 23, 2012
Sales and Marketing Accord, AstraZeneca, Sandoz, Seroquel, Teva

A British High Court has ruled that AstraZeneca’s patent on its new formulation of the antipsychotic Seroquel is invalid. Seroquel …

AstraZeneca image

AstraZeneca pulls depression drug, takes $50m hit

March 20, 2012
Research and Development, Sales and Marketing AstraZeneca, R&D, depression, failure, pipeline

AstraZeneca and partner Targacept will not file their depression drug TC-5214 for regulatory review. The decision comes after disappointing Phase …

AstraZeneca touting for business at partnering conference

March 19, 2012
Research and Development, Sales and Marketing AstraZeneca, Bio-Europe, R&D, partnering

AstraZeneca is marketing itself as a key partner for drug development deals, ahead of a European partnering conference.  The Bio-Europe …

AstraZeneca picture

AstraZeneca sues FDA over generic Seroquel

March 14, 2012
Manufacturing and Production, Sales and Marketing AstraZeneca, FDA, Seroquel, US, generics

AstraZeneca has said it filed a lawsuit against the US FDA in a bid to block approval of generic versions …

AstraZeneca announces several non-executive moves

March 1, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, appointments

AstraZeneca has announced that Leif Johansson is set to be elected as a non-executive director in April, with the intention …

Caprelsa image

Caprelsa approved in Europe for thyroid cancer

February 21, 2012
Sales and Marketing AstraZeneca, Caprelsa, FDA, RET, thyroid cancer

The European Commission has approved AstraZeneca’s thyroid cancer pill Caprelsa. Caprelsa (vandetanib) is now available in Europe for the treatment …

AstraZeneca picture

AstraZeneca to cut 7,300 jobs as growth stalls

February 2, 2012
Business Services, Manufacturing and Production, Research and Development, Sales and Marketing AZ, AstraZeneca, David Brennan, R&D

AstraZeneca will make 7,300 cuts to its sales and R&D staff by 2014, but the company has not yet said …

The Gateway to Local Adoption Series

Latest content